The effect of re-operation on survival in patients with recurrent glioblastoma

Anticancer Research

Volumn 35, Issue 3, 2015, Pages 1743-1748

  Franceschi, Enrico ^a   Bartolotti, Marco ^a   Tosoni, Alicia ^a   Bartolini, Stefania ^a   Sturiale, Carmelo ^a   Fioravanti, Antonio ^a   Pozzati, Eugenio ^a   Galzio, Renato ^b   Talacchi, Andrea ^c   Volpin, Lorenzo ^d   Morandi, Luca ^e   Danieli, Daniela ^d   Ermani, Mario ^f   Brandes, Alba A ^a  

^a BELLARIA HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d SAN BORTOLO HOSPITAL   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Glioblastoma; Radiotherapy; Second surgery; Surgery; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; GLIOBLASTOMA; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REOPERATION; RETROSPECTIVE STUDY; THERAPY EFFECT; ADOLESCENT; BRAIN NEOPLASMS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REOPERATION; RETROSPECTIVE STUDIES;

EID: 84924962625     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J and Brandes A; RARECARE working group: Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 48: 1532-1542, 2012.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG and Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5 years analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
4. Ammirati M, Galicich JH, Arbit E and Liao Y: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21: 607-614, 1987.
5. Landy HJ, Feun L, Schwade JG, Snodgrass S, Lu Y and Gutman F: Retreatment of intracranial gliomas. South Med J 87: 211-214, 1994.
6. Keles GE, Anderson B and Berger MS: The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52: 371-379, 1999.
7. Pinsker M and Lumenta C: Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62: 43-47, 2001.
8. Mandl ES, Dirven CM, Buis DR, Postma TJ and Vandertop WP: Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol 69: 506-509, 2008.
9. McGirt MJ, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD, Brem H and Quiñones-Hinojosa AR: Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110: 156-162, 2009.
10. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA and Black PM: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28: 3838-3843, 2010.
11. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR and Prados MD; North American Brain Tumor Consortium: Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol 13: 1118-1124, 2011.
12. De Bonis P, Fiorentino A, Anile C, Balducci M, Pompucci A, Chiesa S, Sica G, Lama G, Maira G and Mangiola A: The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. Clin Neurol Neurosurg 115: 883-886, 2013.
13. Carson KA, Grossman SA, Fisher JD and Shaw EG: Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25: 2601-2606, 2007.
14. Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D and van den Bent MJ: New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 48: 1176-1184, 2012.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
16. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE and Fine HA: Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28: 1168-1174, 2010.
17. Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P, Gardiman M, Labianca R, Bianchini C, Ermani M and Reni M: Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol 64: 769-775, 2009.
18. Franceschi E, Cavallo G, Scopece L, Paioli A, Pession A, Magrini E, Conforti R, Palmerini E, Bartolini S, Rimondini S, Esposti RD and Crinò L: Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma Br J Cancer 91: 1038-1044, 2004.
19. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M and Cloughesy T: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740, 2009.
20. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007.
21. Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B and van den Bent MJ: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15: 943-953, 2014.
22. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L and Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-22, 2014.
23. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr and Mehta MP: A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370: 699-708, 2014.
24. Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M and Poulsen HS: Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer 13: 402, 2013.
25. Brandes AA, Vastola F and Monfardini S: Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome. Am J Clin Oncol 22: 387-390, 1999.
26. Park CK, Kim JH, Nam DH, Kim CY, Chung SB, Kim YH, Seol HJ, Kim TM, Choi SH, Lee SH, Heo DS, Kim IH, Kim DG and Jung HW: A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma. Neuro Oncol 15: 1096-1101, 2013.